Zacks Investment Research Reaffirms "Buy" Rating for OncoGenex Pharmaceuticals Inc


's stock had its "buy" rating restated by Zacks Investment Research in a report released on Sunday, AnalystRatingsNetwork.com reports. They currently have a $0.75 target price on the biopharmaceutical company's stock.



from Biotech News